ps20 amino acid sequences

Abstract

Urogenital sinus derived growth inhibitory factor is a protein having growth-inhibitory and antiprotease properties. The present invention relates to amino acid and nucleotide sequences for urogenital sinus derived growth inhibitory factor.

What is claimed is:  
     
         1 . An isolated DNA molecule encoding a urogenital sinus derived growth inhibitory factor.  
     
     
         2 . The DNA molecule of  claim 1  wherein said DNA is cDNA.  
     
     
         3 . The DNA molecule of  claim 1  wherein said DNA is genomic DNA.  
     
     
         4 . The DNA molecule of  claim 1  wherein said DNA is human DNA.  
     
     
         5 . The DNA molecule of  claim 4  wherein said DNA is genomic DNA.  
     
     
         6 . The DNA molecule of  claim 1  wherein said DNA is mouse DNA.  
     
     
         7 . The mouse DNA of  claim 6  wherein said DNA is mouse genomic DNA.  
     
     
         8 . The mouse genomic DNA of  claim 7  wherein said mouse genomic DNA comprises the sequence of SEQ ID NOS. 16 or 17.  
     
     
         9 . The DNA molecule of  claim 1  wherein said DNA is rat genomic DNA.  
     
     
         10 . An isolated DNA molecule encoding a WAP four-disulfide core domain 1 gene.  
     
     
         11 . The DNA molecule of  claim 10 , wherein said gene is WFDC1.  
     
     
         12 . The DNA molecule of  claim 10  wherein said gene is Wfdc1.  
     
     
         13 . A recombinant urogenital sinus derived growth inhibitory factor.  
     
     
         14 . The factor of  claim 13  wherein said factor is a human protein.  
     
     
         15 . The factor of  claim 13  wherein said factor is a rat protein.  
     
     
         16 . The factor of  claim 13  wherein said factor is a mouse protein.  
     
     
         17 . An antibody immunologically recognizing urogenital sinus derived growth inhibitory factor.  
     
     
         18 . The antibody of  claim 17  wherein said antibody is a polyclonal antibody.  
     
     
         19 . The antibody of  claim 17  where said antibody is a monoclonal antibody.  
     
     
         20 . A method of detecting the presence of DNA or RNA encoding a urogenital sinus derived growth inhibitory factor in a sample comprising: 
 labeling any of the DNA molecules of claims  1 - 12 , or a fragment thereof;    contacting said labeled DNA or fragment with a sample containing DNA in a manner conducive to DNA-DNA or DNA-RNA hybridization; and, determining if said hybridization takes place by detecting the presence of said labeled DNA or fragment.    
     
     
         21 . The method of  claim 20  wherein said labeling is radiolabeling.  
     
     
         22 . The method of  claim 20  wherein said labeling is fluorescent labeing.  
     
     
         23 . A kit for detecting the presence of DNA or RNA encoding a urogenital sinus derived growth inhibitory factor comprising: 
 labeled DNA as in any of claims  1 - 12 ; and    hybridization reagents.    
     
     
         24 . A method of detecting the presence of a urogenital sinus derived growth inhibitory factor in a sample comprising: 
 labeling any of the antibodies of claims  17 - 19 , or an immunologically reactive fragment thereof;    contacting said labeled antibody or fragment with a sample containing protein in a manner conducive to antibody-antigen cross reactivity; and    determining if said cross reactivity takes place by detecting the presence of said labeled antibody or fragment.    
     
     
         25 . The method of  claim 24  wherein the labeling is radiolabeling.  
     
     
         26 . The method of  claim 25  wherein the labeling is fluorescent labeling.  
     
     
         27 . A method of detecting the presence or localization of DNA or RNA encoding a urogenital sinus derived growth inhibitory factor in a chromosome, comprising: 
 labeling any of the DNA molecules of claims  1 - 12 , or a fragment thereof;    contacting said labelled DNA or fragment with a chromosome in a manner conducive to DNA-DNA or DNA-RNA hybridization; and    determining the presence or localization of said chromosonal DNA encoding said factor on said chromosome.    
     
     
         28 . The method of  claim 27  wherein the labeling is radiolabeling.  
     
     
         29 . The method of  claim 27  wherein the labeling is fluorescent labeling.  
     
     
         30 . The method of  claim 27  wherein the labeling is biotin labeling.  
     
     
         31 . A biologically functional vector comprising a DNA molecule encoding a urogenital sinus derived growth inhibitory factor.  
     
     
         32 . The vector of  claim 31  wherein said DNA molecule is a human DNA.  
     
     
         33 . The vector of  claim 31  wherein said DNA molecule is a rat DNA.  
     
     
         34 . The vector of  claim 31  wherein said DNA molecule is a mouse DNA.  
     
     
         35 . A host cell containing any of the vectors of claims  31 - 34 .  
     
     
         36 . The cell of  claim 39  wherein said cell is prokaryotic.  
     
     
         37 . The cell of  claim 39  wherein said cell is eukaryotic.  
     
     
         38 . A method of making a recombinant urogenital sinus derived growth inhibitory factor comprising: 
 culturing a cell as in any of claims  35 - 37  in a medium;    harvesting said cell from said culture or harvesting said cell culture medium;    extracting said factor from said cell or said medium.    
     
     
         39 . A method of treating a stromal cell comprising: 
 contacting said cell with a urogenital sinus derived growth inhibitory factor.    
     
     
         40 . The method of  claim 39  wherein said stromal cell is a vascular cells.  
     
     
         41 . The method of  claim 39  wherein said stromal cell is a tumor cells.  
     
     
         42 . The method of  claim 39  wherein said stromal cell is an organ smooth muscle cell.  
     
     
         43 . The method of  claim 39  wherein said stromal cell is a stroma cell involved in fibrosis, wound repair or reactive stroma.  
     
     
         44 . A method of genetic therapy comprising: 
 introducing into a patient a vector capable of transfecting said patient with a gene encoded in said vector;    said gene encoding a urogenital sinus derived growth inhibitory factor.    
     
     
         45 . The method of  claim 44  wherein said transfection is permanent.  
     
     
         46 . The method of  claim 44  wherein said transfection is temporary.  
     
     
         47 . The method of  claim 44  wherein said therapy is vascular therapy.  
     
     
         48 . The method of  claim 44  wherein said therapy is cancer therapy.  
     
     
         49 . An affinity chromatographic medium comprising an antibody against a recombinant urogenital sinus derived growth inhibitory factor.